ALX Oncology Holdings Financial Statements (ALXO)
|
|
|
|
Report date
|
|
|
31.12.2019 |
18.03.2021 |
28.02.2022 |
09.03.2023 |
07.03.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
4.80 |
1.18 |
0.000 |
0.000 |
0.000 |
|
2.48 |
|
Operating Income, bln rub |
|
|
-19.2 |
-43.7 |
-83.6 |
-127.4 |
-170.3 |
|
-159.9 |
|
EBITDA, bln rub |
? |
|
-18.8 |
-43.5 |
-83.5 |
-122.0 |
-158.4 |
|
-148.6 |
|
Net profit, bln rub |
? |
|
-19.2 |
-45.7 |
-83.5 |
-123.5 |
-160.8 |
|
-151.2 |
|
|
OCF, bln rub |
? |
|
-14.2 |
-38.3 |
-68.1 |
-89.2 |
-130.4 |
|
-129.5 |
|
CAPEX, bln rub |
? |
|
0.353 |
0.031 |
4.92 |
1.43 |
1.27 |
|
0.535 |
|
FCF, bln rub |
? |
|
-14.6 |
-38.3 |
-73.0 |
-90.7 |
-131.6 |
|
-130.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.003 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
19.6 |
43.8 |
83.6 |
127.4 |
170.3 |
|
159.2 |
|
Cost of production, bln rub |
|
|
4.36 |
1.08 |
0.736 |
1.47 |
0.836 |
|
0.641 |
|
R&D, bln rub |
|
|
16.3 |
29.0 |
60.2 |
98.4 |
141.8 |
|
134.6 |
|
Interest expenses, bln rub |
|
|
0.021 |
0.811 |
0.013 |
0.000 |
1.57 |
|
1.72 |
|
|
Assets, bln rub |
|
|
10.7 |
436.1 |
380.2 |
306.5 |
242.6 |
|
185.7 |
|
Net Assets, bln rub |
? |
|
-0.276 |
-118.5 |
-202.0 |
-325.5 |
189.7 |
|
136.8 |
|
Debt, bln rub |
|
|
5.42 |
0.000 |
0.742 |
10.4 |
17.2 |
|
9.84 |
|
Cash, bln rub |
|
|
9.02 |
434.2 |
363.7 |
282.9 |
182.7 |
|
148.6 |
|
Net debt, bln rub |
|
|
-3.60 |
-434.2 |
-362.9 |
-272.5 |
-165.5 |
|
-138.7 |
|
|
Ordinary share price, rub |
|
|
|
86.2 |
21.5 |
11.3 |
14.9 |
|
7.70 |
|
Number of ordinary shares, mln |
|
|
36.5 |
39.8 |
40.3 |
40.7 |
43.0 |
|
52.7 |
|
|
Market cap, bln rub |
|
|
0 |
3 435 |
866 |
459 |
640 |
|
406 |
|
EV, bln rub |
? |
|
-4 |
3 000 |
503 |
186 |
475 |
|
267 |
|
Book value, bln rub |
|
|
0 |
-119 |
-202 |
-325 |
190 |
|
137 |
|
|
EPS, rub |
? |
|
-0.53 |
-1.15 |
-2.07 |
-3.03 |
-3.74 |
|
-2.87 |
|
FCF/share, rub |
|
|
-0.40 |
-0.96 |
-1.81 |
-2.23 |
-3.06 |
|
-2.47 |
|
BV/share, rub |
|
|
-0.01 |
-2.97 |
-5.01 |
-8.00 |
4.41 |
|
2.60 |
|
|
EBITDA margin, % |
? |
|
-391.1% |
-3 677% |
|
|
|
|
-5 991% |
|
Net margin, % |
? |
|
-401.2% |
-3 870% |
|
|
|
|
-6 095% |
|
FCF yield, % |
? |
|
|
-1.12% |
-8.43% |
-19.8% |
-20.6% |
|
-32.1% |
|
ROE, % |
? |
|
6 972% |
38.6% |
41.3% |
37.9% |
-84.8% |
|
-110.5% |
|
ROA, % |
? |
|
-180.2% |
-10.5% |
-22.0% |
-40.3% |
-66.3% |
|
-81.4% |
|
|
P/E |
? |
|
0.00 |
-75.1 |
-10.4 |
-3.71 |
-3.98 |
|
-2.68 |
|
P/FCF |
|
|
0.00 |
-89.6 |
-11.9 |
-5.06 |
-4.86 |
|
-3.12 |
|
P/S |
? |
|
0.00 |
2 906 |
|
|
|
|
163.6 |
|
P/BV |
? |
|
0.00 |
-29.0 |
-4.29 |
-1.41 |
3.37 |
|
2.97 |
|
EV/EBITDA |
? |
|
0.19 |
-69.0 |
-6.03 |
-1.53 |
-3.00 |
|
-1.80 |
|
Debt/EBITDA |
|
|
0.19 |
9.99 |
4.35 |
2.23 |
1.05 |
|
0.93 |
|
|
R&D/CAPEX, % |
|
|
4 619% |
93 423% |
1 222% |
6 896% |
11 130% |
|
25 164% |
|
|
CAPEX/Revenue, % |
|
|
7.36% |
2.62% |
|
|
|
|
21.6% |
|
| ALX Oncology Holdings shareholders |
